Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy

ClinicalTrials.gov ID: NCT01136655

Public ClinicalTrials.gov record NCT01136655. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This purpose of the study is to investigate the bronchodilating effects of 3 different dosages of formoterol given in combination with budesonide as Symbicort pMDI.

Study identification

NCT ID
NCT01136655
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
54 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Years to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2010
Primary completion
Nov 30, 2011
Completion
Nov 30, 2011
Last update posted
Oct 30, 2013

2010 – 2011

United States locations

U.S. sites
20
U.S. states
9
U.S. cities
20
Facility City State ZIP Site status
Research Site Huntington California
Research Site Long Beach California
Research Site Mission Viejo California
Research Site Orange California
Research Site Rolling Hills Estate California
Research Site Sarasota Florida
Research Site Omaha Nebraska
Research Site Morrisville North Carolina
Research Site Raleigh North Carolina
Research Site Eugene Oregon
Research Site Lake Oswego Oregon
Research Site Medford Oregon
Research Site Portland Oregon
Research Site Altoona Pennsylvania
Research Site Upland Pennsylvania
Research Site Charleston South Carolina
Research Site El Paso Texas
Research Site San Antonio Texas
Research Site Waco Texas
Research Site Springfield Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

Recently updated Asthma trials

Other public records listing Asthma. Sorted by last update posted; newest first. Not a recommendation.

All Asthma trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01136655, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 30, 2013 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01136655 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →